drugset
drugset / Trial / NCT01605994

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

NCT01605994 ↗

Phase 1 Completed 115 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindBasic science

Summary

Includes a placebo-controlled sequential, ascending multiple-dose panels (10 panels, 8 ascending doses, and 2 fixed Japanese Panels exploring safety, tolerability, and Pharmacokinetic (PK) measures

Timeline

Start
2012-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-933043 Unknown 2 mg Oral
Subject BMS-933043 Unknown 5 mg Oral
Subject BMS-933043 Unknown 10 mg Oral
Subject BMS-933043 Unknown 25 mg Oral
Subject BMS-933043 Unknown 50 mg Oral
Subject BMS-933043 Unknown 100 mg Oral
Subject BMS-933043 Unknown 200 mg Oral
Subject BMS-933043 Unknown 350 mg Oral

Indications

No indication recorded.